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Introduction
Angiogenesis, the growth of blood vessels, has received con-
siderable attention over the past few decades, and the first 
antiangiogenic pharmaceuticals have recently entered the 
clinics. However, the molecular mechanisms regulating lymp-
hangiogenesis, the growth of lymphatic vessels, are far less 
explored. Yet understanding the functions and regulatory path-
ways of this vascular system will undoubtedly lead to novel and 
significant paradigms in both biology and clinical medicine.
Lymphatic vessels regulate tissue fluid homeostasis, immune 
cell trafficking, and absorption of dietary fats. The absence 
of lymphatic vessels is incompatible with life, and individuals 
with dysfunctional lymphatic vessels often suffer from chronic 
edema and impaired immune responses. Our knowledge of 
the molecular mechanisms controlling lymphangiogenesis has 
improved considerably over the past few years, mainly thanks 
to progress in the identification of regulatory molecules and 
markers specific to the lymphatic endothelium. The genetic 
programs that determine lymphatic endothelial cell (LEC) dif-
ferentiation and growth, and make them distinct from blood 
vessels, involve a number of newly described signal transduc-
tion pathways.
Importantly, lymphangiogenesis occurs in adult tissues dur-
ing inflammation, wound healing, and tumor metastasis. Con-
sequently, administration of lymphatic growth factors or their 
antagonists provides the possibility of targeting lymphatic ves-
sels in human disease. In this Review we discuss the recent 
advances that have greatly improved our understanding of the 
biology behind lymphangiogenesis, including the management 
of inflammation, obesity, hypertension, tumor metastasis, and 
lymphatic vessel dysfunction.
Functions of the Lymphatic Vascular System
Large multicellular organisms such as humans need a circu-
latory system to distribute oxygen, nutrients, hormones, and 
even cells to tissues, as well as to collect carbon dioxide and 
other metabolic waste products. The blood contains a variety 
of colloid proteins that help to maintain its water content higher 
than in the surrounding tissues. Blood pressure causes plasma 
constituents to filtrate continuously from the arterial side of the 
capillary bed into the interstitial space. Approximately 90% of 
the extravasated water is reabsorbed at the venous side of the 
capillary bed, where the colloid osmotic pressure of the blood 
exceeds the blood pressure. The main function of the lym-
phatic vasculature is to return the remaining 10% back to the 
blood vascular system (Földi and Strössenreuther, 2004).
Fluid, macromolecules, and certain leukocytes enter blind-
ended lymphatic capillaries, which connect with larger collect-
ing lymphatic vessels (Figure 1). Lymph from the left side of 
the body, abdomen, and both lower limbs ends up in the tho-
racic duct, the largest lymphatic vessel that runs alongside the 
aorta, and finally connects with the left subclavian vein. Lymph 
from the right upper arm, thorax, and head is returned to the 
right subclavian vein via the right lymphatic trunk (Jeltsch et 
al., 2003). In healthy adult individuals, the lymphatic system 
returns approximately 1–2 liters of interstitial fluid with 20–30 g 
of protein per liter to the venous circulation every day (Levick, 
1999). The collecting lymphatic vessels connect with chains of 
lymph nodes that perform a sieving function (Figure 1C). Thus 
the lymphatic vascular system also plays an important role in 
immune responses by serving as a conduit for extravasated 
leukocytes and activated antigen-presenting cells. In the small 
intestine, lacteal lymphatic vessels inside the intestinal villi 
absorb dietary lipids released by intestinal epithelial cells in 
the form of chylomicrons.
Lymphatic vessels are typically found in all vascularized tis-
sues, with the notable exception of bone marrow and the cen-
tral nervous system. However, some connections between the 
cerebrospinal fluid and lymphatic vascular systems exist, and 
lymphatic vessels are capable of partly compensating for the 
drainage of intracranial fluid when clearance of the cerebrospi-
nal fluid is compromised (Johnston et al., 2004). Besides the 
fat-absorbing small intestine, tissues that frequently become 
in contact with foreign antigens, such as the skin and mucous 
membranes, are particularly rich in lymphatic vessels. The lym-
phatic vascular system is found at least in vertebrates such as 
teleost fish, amphibians, reptiles, and mammals (Jeltsch et al., 
2003; Kuchler et al., 2006; Ny et al., 2005; Yaniv et al., 2006), 
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whose complex cardiovascular system and relatively large 
body size require the presence of a secondary vascular system 
for the maintenance of fluid balance.
The lymphatic capillaries form the absorptive part of the 
lymphatic vascular tree, being responsible for the uptake of 
interstitial fluid, macromolecules, and cells that collectively are 
called lymph, once inside the lymphatic vessels. The lymphatic 
capillaries are blind-ended and thin-walled vessels of approxi-
mately 30–80 µm in diameter and composed of a single layer 
of LECs, which are not ensheathed by pericytes or smooth 
muscle cells, have little or no basement membrane, and dis-
play distinct gene expression patterns (Alitalo et al., 2005; 
Maby-El Hajjami and Petrova, 2008; Wick et al., 2007) (Figure 
1). In contrast to continuous interendothelial junctions in blood 
vessels, lymphatic capillaries have discontinuous or “button-
like” junctions (Baluk et al., 2007; Tammela et al., 2007). The 
interjunctional gaps act as sites of leukocyte entry into the ves-
sels. These structural features render the walls of the lymphatic 
capillaries highly permeable, which enables optimal uptake of 
lymph components. Furthermore, the lymphatic capillaries are 
connected to the surrounding extracellular matrix by anchoring 
filaments, which attach to collagen fibers so that they become 
taut in conditions of tissue swelling, resulting in opening of the 
lymphatic vessel lumen, decreased intralumenal pressure, and 
increased uptake of tissue fluid (Figure 1A). The anchoring fila-
ments are mainly composed of emilin-1 and fibrillin, which may 
attach to the LECs via adhesion molecules such as αvβ3 integ-
rin (Danussi et al., 2008; Maby-El Hajjami and Petrova, 2008).
Lymph moves from the lymphatic capillary bed into precol-
lector vessels, which are sparsely covered by smooth muscle 
cells (Maby-El Hajjami and Petrova, 2008). The precollec-
tor vessels fuse with collecting lymphatic vessels, which are 
characterized by the presence of a smooth muscle cell layer, a 
basement membrane, continuous “zipper-like” interendothelial 
junctions, and bileaflet valves (Alitalo et al., 2005; Baluk et al., 
2007). The intrinsic contractility of smooth muscle cells as well 
as the contraction of surrounding skeletal muscles and arterial 
pulsations are necessary for lymph propulsion, whereas valves 
prevent lymph backflow (Bazigou et al., 2009) (Figure 1B). In 
this respect, the collecting lymphatic vessels resemble small 
veins.
The LECs are terminally differentiated cells distinct from 
blood vascular endothelial cells (Saharinen et al., 2004; Wick 
et al., 2007). This has enabled the discovery of lymphatic 
Figure 1. Anatomy of the Lymphatic Vascular System
(A) Interstitial fluid, macromolecules, and cells enter lymphatic capillaries through interendothelial gaps, which are sealed by overlapping oak-leaf-shaped 
lymphatic endothelial cells (LECs) when the vessel is filled. Lymphatic vessel hyaluronan receptor-1 (LYVE-1) immunostaining (green) shows a blind end of a 
lymphatic capillary in a whole-mount preparation of the mouse ear skin. 
(B) From the capillaries lymph moves to precollectors and on to collecting vessels, directed by minute changes in interstitial fluid pressure and the negative 
pressure within the lymphatic vascular system. Collecting lymphatic vessels are specialized for the transport of lymph; they do not absorb fluid from surround-
ing tissues. These vessels are surrounded by a basement membrane and a smooth muscle cell layer and contain bileaflet intralumenal valves to prevent lymph 
backflow. Confocal images are of whole-mount preparations of the mouse ear following intradermal injection of Lycopersicon esculentum lectin (green), which 
marks lymphatic valves, and immunostaining with antibodies to smooth muscle α-actin (red). Nuclear staining in blue. 
(C) Afferent collecting vessels connect with lymph nodes, which process foreign antigens that are found soluble in the lymph as well as presented by antigen-
presenting cells. Lymph leaves the lymph node via an efferent vessel and finally reaches the venous system via the thoracic duct or the right lymphatic duct 
that connect with the subclavian veins at the venous angles. Images adapted by permission from Macmillan Publishers Ltd: Nature (Tammela et al., 2007), 
copyright 2007. LV, lymphatic vessel.
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vascular-specific molecules that are used for identification of 
lymphatic vessels in tissues, as well as for finding targets for 
the specific induction or inhibition of lymphatic vessel growth 
in pathological conditions (reviewed in Saharinen et al., 2004). 
These include the prospero-related homeodomain transcrip-
tion factor Prox1, the membrane glycoprotein podoplanin, 
vascular endothelial growth factor receptor-3 (VEGFR-3), and 
lymphatic vessel hyaluronan receptor-1 (LYVE-1).
Development of the Lymphatic Vascular Tree
Commitment to Lymphatic Endothelium
The lymphatic vessels arise after the cardiovascular system is 
established and functional (Figure 2). Lymphatic vessel devel-
opment starts at about embryonic weeks 6–7 in humans and at 
embryonic day (E) 9.5–10.5 in mice, when distinct subpopulations 
of endothelial cells in the lateral parts of the anterior cardinal veins 
commit to the lymphatic lineage and then sprout laterally to form 
primordial lymphatic vascular structures, the lymph sacs (Alitalo 
et al., 2005; Oliver, 2004; Wigle and Oliver, 1999). The peripheral 
lymphatic vasculature is then generated by centrifugal sprouting 
of lymphatic vessels from the lymph sacs, followed by merging 
of the separate lymphatic capillary networks and remodeling and 
maturation of the primitive lymphatic capillary plexus (Figure 2).
Genetic experiments in mice have validated that mammalian 
lymphatic vessels originate from embryonic veins (Karkkainen et 
al., 2004; Oliver, 2004; Srinivasan et al., 2007; Wigle and Oliver, 
1999), as postulated already in 1902 by the American anatomist 
Florence Sabin. Further validation of this view has been obtained 
from lineage-tracing experiments in mice (Srinivasan et al., 
2007), and dynamic imaging in developing zebrafish embryos 
has elegantly demonstrated that this process is conserved in 
evolution (Kuchler et al., 2006; Yaniv et al., 2006). These pioneer-
ing studies have demonstrated the versatility and speed of the 
zebrafish as a model organism in the discovery of new molecular 
mechanisms regulating the development of the lymphatic ves-
sels, although it should be noted that the differentiation of col-
lecting lymphatic vessels has not been reported in fish (Hogan 
et al., 2009) (Figure S1 available online).
LYVE-1, one of the most specific and widely used lymphatic 
endothelial markers, is expressed in a subset of endothelial 
cells in the large central veins and currently provides the first 
indicator of lymphatic endothelial competence (Jurisic and Det-
mar, 2009; Maby-El Hajjami and Petrova, 2008) (Figure 2B). In 
adults its expression in collecting lymphatic vessels decreases 
and remains high only in lymphatic capillaries (Makinen et al., 
2005). However, gene targeting in mice indicates that LYVE-1 
is dispensable for normal lymphatic development or function 
(Gale et al., 2007).
Prox1 is specific for lymphatic vessels in the vascular system. 
In mice, the first Prox1-positive endothelial cells are detected as 
a restricted subpopulation on one side of the anterior cardinal 
Figure 2. Development of the Mammalian Lymphatic Vasculature
(A) After differentiation from angioblasts, endothelial cells undergo arterial-
venous (AV) specification. 
(B) Embryonic veins express high levels of VEGFR-3, whereas a subpopula-
tion of endothelial cells in the large central veins upregulate LYVE-1 (lymphatic 
vessel hyaluronan receptor-1). 
(C) The transcription factor SOX18 is induced in the LYVE-1-positive lymphat-
ic endothelial cell (LEC) precursors. 
(D) SOX18 induces Prox1 expression, the first marker for LEC determination. 
At about this time, VEGFR-3 expression is downregulated in the blood ves-
sels, but it remains high in the LEC precursors, which also begin to express 
neuropilin-2, rendering them more responsive to VEGF-C signals arising from 
the lateral mesenchyme. These signals are required for sprouting of the LECs, 
which form lymph sacs lateral to the central veins. 
(E) The LECs begin to express podoplanin, which via the CLEC-2 receptor 
activates the Syk tyrosine kinase in platelets. This leads to platelet aggrega-
tion, which blocks lymphatico-venous connections and helps to separate the 
blood and lymphatic vascular systems. 
(F) Further centrifugal growth of the lymphatic vessel network ensues, driven 
by VEGF-C/VEGFR-3 and possibly Ccbe1 signals. 
(G) The final steps of lymphatic vascular development involve differentiation to 
lymphatic capillaries and collecting lymphatic vessels. The latter form intralu-
menal valves, recruit smooth muscle cells, develop continuous interendothe-
lial junctions, and produce a basement membrane.
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vein at E9.5, and soon thereafter these cells start budding from 
the vein and migrating in a polarized manner, eventually form-
ing lymph sacs (Oliver, 2004; Wigle and Oliver, 1999) (Figures 
2D and 2E). Prox1 knockout embryos lack lymph sacs and lym-
phatic vessels. The Prox1-deficient endothelial cells initially bud 
and sprout from the cardinal vein, although in an unpolarized 
manner, but their migration is soon arrested. These cells fail to 
express lymphatic endothelial markers and instead retain their 
blood vascular endothelial phenotype (Oliver, 2004; Wigle and 
Oliver, 1999). Overexpression of Prox1 in human blood vascular 
endothelial cells (BECs) suppresses the expression of several 
genes specific for the blood vascular endothelium and upregu-
lates LEC-specific gene expression (Alitalo et al., 2005; Jurisic 
and Detmar, 2009; Oliver, 2004), which further suggests a func-
tion for Prox1 as a master switch that determines LEC fate.
The signals leading to polarized expression of PROX1 in dif-
ferentiating LECs are currently poorly understood. In a recent 
study, Francois et al. demonstrated that the homeobox tran-
scription factor SOX18 is expressed in cardinal vein endothe-
lial cells prior to Prox1, and that the Prox1 promoter contains 
SOX18-binding sites, indicating that SOX18 is required for ini-
tiation of the LEC differentiation program upstream of Prox1 
(Francois et al., 2008) (Figure 2C). Gene targeting of the SOX18 
locus or homozygous expression of a dominant-negative 
mutant SOX18 abolished Prox1 expression and led to edema 
and embryonic lethality (Francois et al., 2008). Interestingly, 
loss of even one allele or heterozygous dominant-negative 
mutation of SOX18 leads to defects in the patterning of the 
cutaneous lymphatic vessels (Francois et al., 2008). However 
SOX7 and SOX17 can be upregulated in the absence of SOX18, 
which may modify the mutant phenotype (Hosking et al., 2009). 
At present, the signals leading to the induction of SOX18 in 
cells committing to the LEC lineage remain unknown.
Studies in nonmammalian species have led to an alterna-
tive view of a dual origin from embryonic veins and mesenchy-
mal lymphangioblasts. Grafting experiments in avian embryos 
Figure 3. Key Molecular Pathways Regulating Lymphangiogenesis
The transcription factor Prox1 drives expression of lymphatic endothelial-specific genes, whereas FOXC2 and NFAT1c regulate differentiation of the lymphatic 
collecting vessel phenotype. Podoplanin activates the CLEC-2 receptor in platelets, leading to the activation of the tyrosine kinase Syk and platelet aggregation. 
This mechanism is important for the separation of blood and lymphatic vascular systems (also see Figure 2). TGF-β and IFN-γ act as endogenous inhibitors of 
lymphangiogenesis. Note VEGFR and Tie expression in both lymphatic and blood vascular endothelial cells.
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suggest that although the deep parts of the lymph sacs are 
derived from adjacent veins, the superficial parts of the jugular 
lymph sacs and the dermal lymphatics arise from local lymp-
hangioblasts (Wilting et al., 2006). In Xenopus laevis tadpoles, 
Prox1-positive mesodermal precursor cells, lymphangioblasts, 
which share a common origin with vascular progenitor cells, 
contribute to lymphatic vessel formation (Ny et al., 2005). It is 
not yet known how these cells relate to the parachordal lym-
phatic precursors described in zebrafish (Figure S1). Also in 
murine embryos, scattered mesenchymal cells, which coex-
press leukocyte (CD45) and lymphatic endothelial markers 
(LYVE-1, Prox1), were detected in the regions of new lymphatic 
vessel growth, and it is suggested that these cells with char-
acteristics of LECs and macrophages integrate into lymphatic 
vessels (Buttler et al., 2006, 2008). However, the formation of 
lymph sacs is not affected in Runx1 gene-targeted mice, which 
have defective hematopoiesis, and lineage-tracing studies fail 
to confirm contribution of hematopoietic cells to lymphatic 
endothelium (Buttler et al., 2008; Srinivasan et al., 2007). It 
is conceivable that hematopoietic cells contribute to devel-
opmental lymphangiogenesis by providing paracrine factors, 
as has been described previously for angiogenesis (Tammela 
et al., 2005a). At least macrophages appear to be important 
sources of lymphangiogenic factors, as postnatal lymphatic 
vessel development is delayed in op/op mice, which harbor an 
inactivating mutation in the csf1 gene that encodes monocyte 
colony-stimulating factor (M-CSF), leading to loss of mac-
rophages (Kubota et al., 2009).
Expansion of the Lymphatic Vascular Tree by Migration 
and Proliferation
The receptor tyrosine kinase VEGFR-3 was one of the first 
lymphatic endothelial markers to be discovered (Alitalo et al., 
2005; Karpanen and Alitalo, 2008). VEGFR-3 is activated by 
VEGF-C and VEGF-D, both members of the VEGF family of 
growth factors (Achen et al., 2005; Karpanen and Alitalo, 2008). 
VEGFR-3 can form heterodimers with VEGFR-2 upon binding 
of the mature, proteolytically processed forms of VEGF-C and 
VEGF-D, which may lead to unique combinatorial signals by the 
intracellular domains of the two receptors (Olsson et al., 2006) 
(Figure 3). VEGFR-3 is present in all endothelia during early 
stages of development, and Vegfr3 gene-targeted mice die at 
around E10.5 due to defective development of the cardiovas-
cular system (Alitalo et al., 2005; Karpanen and Alitalo, 2008). 
Endothelial cells committed to the lymphatic lineage express 
high levels of VEGFR-3, and as the lymphatic vascular system 
begins to develop, VEGFR-3 expression becomes restricted 
exclusively to LECs with the exception of the fenestrated blood 
vessels found in endocrine organs such as the thyroid, the 
adrenal glands, and pancreas (Tammela et al., 2005a).
Whereas VEGF, PlGF, and VEGF-B isoforms are formed 
through alternative splicing, the different forms of VEGF-C and 
VEGF-D are the result of proteolytic processing. Both growth 
factors are produced as precursor proteins, which are activated 
by intracellular proprotein convertases (Achen et al., 2005; Ali-
talo et al., 2005; Karpanen and Alitalo, 2008). The secreted, 
disulphide-linked VEGF-C subunits only bind VEGFR-3, but the 
factor is further proteolyzed in the extracellular environment by 
plasmin and other proteases to generate non-disulfide-linked 
homodimeric proteins with high affinity for both VEGFR-2 and 
VEGFR-3 (Alitalo et al., 2005; Karpanen and Alitalo, 2008). 
VEGF-C and VEGF-D both induce proliferation, migration, and 
survival of endothelial cells (Tammela et al., 2005a).
During development, VEGF-C is expressed predominantly 
in regions where lymphatic vessels develop (Karkkainen et al., 
2004; Karpanen and Alitalo, 2008) (Figure 2C). In mice, Xeno-
pus tadpoles, and zebrafish where Vegfc has been inactivated, 
LECs initially differentiate in the embryonic veins but fail to 
migrate and form the primary lymph sacs (Karkkainen et al., 
2004; Kuchler et al., 2006; Yaniv et al., 2006). Homozygous 
deletion of Vegfc leads to the complete absence of a lymphatic 
vascular system in mouse embryos, and Vegfc heterozygous 
mice display severe lymphatic hypoplasia, indicating an analo-
gous haploinsufficient requirement of VEGF-C for lymphangio-
genesis as has been described for VEGF in angiogenesis 
(Karkkainen et al., 2004). In contrast, deletion of Vegfd does 
not affect development of the lymphatic vasculature in mice 
(Baldwin et al., 2005; Karkkainen et al., 2004). Interestingly, 
compound deletion of both Vegfc and Vegfd fails to recapitu-
late the early embryonic lethality observed in Vegfr3 null mice 
(Haiko et al., 2008), suggesting the existence of as yet unidenti-
fied factors capable of activating VEGFR-3.
Transgenic overexpression of a soluble VEGFR-3—immuno-
globulin G Fc-domain fusion protein (“VEGF-C/D Trap”)—from 
E14.5 onward in mouse embryos results in severe hypoplasia 
of the lymphatic vessels (Makinen et al., 2001), indicating that 
VEGF-C/VEGFR-3 signaling plays a key role in further devel-
opment of the lymphatic vascular tree following formation of 
the lymph sacs. Also an endogenous soluble form of VEGFR-2 
appears to block VEGF-C signaling in the cornea, which is 
devoid of lymphatic vessels (Albuquerque et al., 2009). Inter-
estingly, the VEGF-C/D Trap or VEGFR-3 blocking monoclonal 
antibodies induce regression of the already developed lym-
phatic vessels during the first 2 postnatal weeks, but lymphatic 
vessel regrowth is observed at 4 weeks of age despite sus-
tained VEGFR-3 pathway inhibition (Karpanen et al., 2006b). 
Prolonged inhibition does not affect adult lymphatic vessels 
(Lin et al., 2005), indicating that VEGF-C/VEGFR-3 signaling is 
not required for the maintenance of the lymphatic vasculature 
in adulthood.
The axon guidance receptor neuropilin-2 (NP-2) is expressed 
in veins and lymphatic vessels, and Np2 mutant mice have 
lymphatic capillary hypoplasia (Yuan et al., 2002) (Figure 3D). 
Interestingly, both VEGF-C and VEGF-D bind to NP-2, which is 
internalized with VEGFR-3 upon ligand stimulation (Karpanen 
et al., 2006a). NP-2 does not have enzymatic signaling activity, 
but NP-2 and VEGFR-3 may collaborate to increase the affin-
ity of LECs toward VEGF-C/D to enable maximal sensing of 
growth factor gradients (Figure 3). Interestingly, NP-2 blocking 
antibodies arrest initial lymphatic sprout elongation stimulated 
by VEGF-C but do not affect further growth of lymphatic ves-
sels (Xu et al., 2010).
Overexpression of VEGF-C or VEGF-D or their VEGFR-3-
specific forms in adult tissues stimulates lymphangiogenesis 
(Karpanen and Alitalo, 2008). Importantly, damaged collecting 
lymphatic vessels can also be regenerated via lymphatic capil-
laries undergoing an intrinsic maturation program in response 
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to VEGF-C or VEGF-D stimulation (Ikomi et al., 2008; Tammela 
et al., 2007). VEGFR-2 is expressed at low levels in the LECs, 
and adenoviral or transgenic overexpression of VEGF in the 
skin induces mainly lymphatic vessel enlargement but very 
little sprouting (Alitalo et al., 2005; Karpanen and Alitalo, 2008; 
Wirzenius et al., 2007).
Although fibroblast growth factor 2 (FGF-2), insulin-like 
growth factor 1 (IGF-1), IGF-2, hepatocyte growth factor (HGF), 
endothelin-1 (ET-1), and PDGF-B have been reported to induce 
lymphangiogenesis in various contexts, most of these effects 
may be secondary to the induction of VEGF-C and VEGF-D in a 
variety of cell types, such as inflammatory cells and fibroblasts 
(Alitalo et al., 2005; Karpanen and Alitalo, 2008). Because of 
other early-onset phenotypes and lethality resulting from 
global gene targeting of these growth factors, it is not known 
whether they directly contribute to the development of the lym-
phatic vascular system.
A recent study using forward genetic screening in the 
zebrafish identified ccbe1 as a regulator of lymphatic vessel 
formation (Hogan et al., 2009). Ccbe1 encodes a secreted 
collagen and calcium-binding EGF-domain-1 protein, whose 
receptor is as yet unidentified. Lymphangioblasts in ccbe1 
gene-targeted fish fail to sprout from the primitive veins and 
form the parachordal lymphatic precursor, a lumenless sin-
gle chord of precursor cells acting as a source of LECs; this 
leads to a complete lack of lymphatic vessels, similar to when 
vegfc is targeted (Hogan et al., 2009) (Figures 2C and 2D). The 
expression of ccbe1 overlaps with vegfc in the somitic meso-
derm (Hogan et al., 2009), suggesting a connection between 
the two signaling pathways, but further studies, such as the 
identification of the Ccbe1 receptor, are required to understand 
its function (Figure 3). Also knockdown of the lysophosphatidic 
acid (LPA) receptor lpa1 in zebrafish prevents formation of the 
thoracic duct, although the mechanism remains unclear, as it is 
not known whether lpa1 is expressed in the lymphatic endothe-
lium (Lee et al., 2008).
In adults, lymphangiogenesis occurs physiologically during 
development of the corpus luteum and wound healing (Alitalo 
et al., 2005; Otsuki et al., 1986). Lymphatic vessel growth is also 
associated with a number of pathological conditions, includ-
ing tumor metastasis, inflammation, and transplant rejection 
(Achen et al., 2005; Alitalo et al., 2005; Cueni and Detmar, 2008). 
Adult lymphangiogenesis occurs primarily by sprouting from 
pre-existing vessels (Alitalo et al., 2005; He et al., 2004, 2005), 
although bone-marrow-derived cells, such as macrophages, 
may transdifferentiate into lymphatic endothelium at least in 
human kidney transplants (Kerjaschki et al., 2004, 2006), in a 
mouse model of corneal injury (Maruyama et al., 2005), and in 
murine tumor models (Zumsteg et al., 2009).
Association of Lymphatic Vessels with the Extracellular 
Matrix
LEC anchorage to the extracellular matrix is dramatically dif-
ferent when compared to BECs, as evidenced by the vesti-
gial basement membrane surrounding LECs. The molecular 
mechanisms regulating LEC association with the extracellular 
matrix are largely unknown. The elastic microfibril-associated 
protein Emilin1 is a component of the anchoring filaments in 
lymphatic vessels (Danussi et al., 2008). Emilin1-deficient mice 
have hyperplastic and disorganized lymphatic vessels with 
a reduced number of anchoring filaments and dysfunctional 
junctions, and they also show impaired lymphatic drainage 
function (Danussi et al., 2008).
Interestingly, targeted inactivation of integrin α9, which forms 
heterodimers with integrin β1, causes fatal chylothorax in mice 
(Huang et al., 2000). Recent exciting work by Bazigou et al. 
(2009) reveals that endothelial cell-specific deletion of Itga9 
(encoding integrin α9) in mouse embryos results in the forma-
tion of dysplastic lymphatic valve leaflets, characterized by 
disorganized fibronectin matrix, short cusps, and retrograde 
lymphatic flow. Similar morphological and functional defects 
are observed in mice lacking the EIIIA domain of fibronectin, 
which is a ligand for integrin α9 (Bazigou et al., 2009) (Figure 
3), indicating that LEC interactions with the extracellular matrix 
play a key role in lymphatic valve formation.
Disconnection from the Blood Vessels
During the course of development, connections between the 
lymphatics and veins are lost, except at the sites where lymph 
mixes with the blood in the subclavian veins (Figure 2E). Mice 
with homozygous mutations in either the tyrosine kinase Syk 
or its adaptor protein SLP-76 (Lcp2) develop arterio-venous 
shunts and abnormal lymphatico-venous connections (Abta-
hian et al., 2003). Syk and Slp76 are expressed almost exclu-
sively in hematopoietic cells, suggesting that these cells con-
tribute to the separation of the two vascular systems (Abtahian 
et al., 2003; Sebzda et al., 2006). Interestingly, genetic ablation 
of Syk causes accumulation of leukocytes that is associated 
with lymphatic hyperproliferation and lymphatic vessel dila-
tion, ultimately resulting in the formation of blood-lymphatic 
shunts (F. Kiefer, personal communication). A phenotype that 
closely resembles the one observed in Syk or Slp76 gene-tar-
geted embryos (Abtahian et al., 2003) occurs in mice deleted 
of Spred-1 and Spred-2, which suppress the phosphorylation 
of the MAP kinase ERK following VEGF-C/VEGFR-3 signaling. 
This results in embryonic lethality by E15.5 with marked sub-
cutaneous hemorrhage, edema, and dilated lymphatic vessels 
filled with blood (Taniguchi et al., 2007).
Podoplanin (also known as T1α, E11 antigen, gp38, and 
PA2.26) is a small O- and N-glycosylated transmembrane pro-
tein expressed at E11.5 in the cardinal vein and later in Prox1-
positive LECs (Breiteneder-Geleff et al., 1999; Schacht et al., 
2003). Among other phenotypes, podoplanin gene-targeted 
mice have dilated and dysfunctional lymphatic vessels, as well 
as lymphedema (Schacht et al., 2003). Importantly, the separa-
tion of the lymphatic vessels from the blood vessels critically 
involves platelet activation by podoplanin. Platelet aggre-
gates build up in wild-type embryos at the separation zone of 
podoplanin-positive lymph sacs and cardinal veins but not in 
podoplanin knockout embryos or in embryos where platelet 
aggregation is inhibited pharmacologically (Uhrin et al., 2010). 
Podoplanin activates C-type lectin receptor 2 (CLEC-2) in plate-
lets and promotes platelet aggregation with a long lag phase 
(Suzuki-Inoue et al., 2007). Interestingly, CLEC-2 activation 
leads to activation of Syk via SLP76 in the platelets (Suzuki-
Inoue et al., 2006), indicating a mechanism for the initial steps 
of blood and lymphatic vessel separation during development 
(Figures 2E and 3).
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Also mice lacking T-synthase, a glycosyltransferase encoded 
by the gene C1galt1 that is essential for the biosynthesis of core 
1-derived O-glycans, in hematopoietic and endothelial cells 
display embryonic or neonatal lethality associated with disor-
ganized and blood-filled lymphatic vessels, mosaic expression 
of LEC markers, and incomplete separation of blood and lym-
phatic vessels (Fu et al., 2008). Podoplanin expression is dra-
matically reduced in the lymphatic vessels of C1galt1 mutant 
mice, suggesting that O-glycosylation is required for normal 
podoplanin function (Fu et al., 2008).
Notably, fasting-induced adipose factor (Fiaf, or angiopoie-
tin-like protein 4, Angptl4) appears to regulate the separation 
of lymphatic and blood vessels specifically in the intestine. 
Angptl4 gene-targeted mice develop normally until birth but 
have blood-filled intestinal lymphatic vessels and decreased 
Prox1 expression postnatally (Backhed et al., 2007). Interest-
ingly, Angptl4 is an inhibitor of lipoprotein lipase (Sukonina et 
al., 2006), which points to a connection between the intestinal 
phenotype and processing of dietary fats.
Remodeling and Maturation of Primitive Lymphatic 
Vessels
Remodeling of the blood vasculature into arteries, capillar-
ies, and veins is required for the development of a functional 
blood vessel network. Similarly, remodeling of the lymphatic 
vasculature includes sprouting of lymphatic capillaries from 
the primary lymphatic plexus, whereas deeper lymphatic ves-
sels recruit smooth muscle cells and develop lymphatic valves, 
acquiring a collecting vessel phenotype (Karpanen and Alitalo, 
2008; Maby-El Hajjami and Petrova, 2008) (Figure 2G).
The ephrins and their Eph tyrosine kinase receptors have been 
implicated in repulsive axon guidance in the nervous system and 
in controlling blood vessel remodeling (Adams, 2002). Mice having 
a mutant C-terminal PDZ domain of ephrinB2 have normal blood 
vasculature, but they have hyperplasia of the collecting lymphatic 
vessels, lack lumenal valve formation, and fail to remodel the pri-
mary lymphatic capillary plexus (Makinen et al., 2005).
The angiopoietin (Ang) growth factors bind to the recep-
tor tyrosine kinase Tie2 that is expressed almost exclusively in 
endothelial cells and regulate interactions between endothelial 
cells and mural cells (Augustin et al., 2009). Tie2 and its close 
homolog Tie1 are expressed at low levels in LECs, which express 
abundant Ang2 levels in both culture conditions and in vivo (Ali-
talo et al., 2005; Norrmén et al., 2009; Wick et al., 2007) (Figure 3). 
Interestingly, Tie1 gene-targeted embryos have dysplastic lymph 
sacs and edema starting from E12.5, indicating that Tie1 may 
modulate Ang signals in LECs (D’Amico et al., 2009). Ang2 knock-
out mice show incomplete regression of hyaloid blood vessels 
and defective lymphatic vessel maturation, including impaired 
smooth muscle cell recruitment to the collecting vessels and hyp-
oplastic lymphatic capillaries, suggesting that Ang2 is needed 
for lymphatic vessel stabilization (Gale et al., 2002). Furthermore, 
transgenic overexpression of Ang2 in LECs produced a similar 
collecting vessel phenotype (M. Lohela, G. D’Amico, K.A., et al., 
unpublished data), indicating a requirement for a delicate balance 
in Ang/Tie signaling during lymphatic vessel maturation. Notably, 
replacement of the Ang2 gene with a cDNA encoding Ang1 is 
sufficient to rescue the lymphatic phenotype but not the blood 
vascular phenotype (Gale et al., 2002). Overexpression of Ang1, 
Ang2, and Ang3/Ang4 in adult tissues promotes lymphangiogenic 
sprouting in several in vivo model systems, with Ang1 being the 
most potent lymphangiogenic factor (Kim et al., 2007; Morisada et 
al., 2005; Tammela et al., 2005b).
The forkhead transcription factor FoxC2 is highly expressed in 
the developing lymphatic vessels as well as in lymphatic valves 
in adults (Dagenais et al., 2004; Petrova et al., 2004). Although 
the early development of lymphatic vessels proceeds normally 
in the absence of Foxc2, the collecting lymphatic vessels lack 
valves, and the lymphatic capillaries acquire an ectopic cover-
age by basement membrane components and smooth muscle 
cells (Petrova et al., 2004). This indicates that FoxC2 controls 
the genetic program responsible for the specification of the lym-
phatic capillary versus collecting lymphatic vessel phenotype 
(Figure 3). In a recent study, Norrmén et al. find that, downstream 
of VEGFR-3, the nuclear factor of activated T cells (NFATc)-1 and 
FoxC2 cooperatively control the expression of the set of genes 
required for the differentiation of lymphatic capillaries and valves 
(Norrmén et al., 2009). Upon further maturation, the collecting 
lymphatic vessels downregulate FoxC2, which leads to reduced 
expression levels of Prox1, VEGFR-3, and LYVE-1 (Norrmén et 
al., 2009). Interestingly, FoxC2 null mice and mice treated with the 
NFATc-1 inhibitor cyclosporin A display increased expression of 
Ang2 in the lymphatic endothelium, pointing to an intriguing link 
with the phenotype observed in Ang2 gene-targeted mice (Gale 
et al., 2002; Norrmén et al., 2009). These observations suggest 
that Ang2 stimulates smooth muscle cell recruitment to the col-
lecting vessels downstream of NFATc-1 and FoxC2 (Figure 3).
Mice deficient in the vasodilator and diuretic peptide 
adrenomedullin (AM) or components of its receptor complex 
(calcitonin receptor-like receptor and receptor activity-modify-
ing protein 2 [RAMP2]) develop edema and embryonic lethality 
at midgestation (Fritz-Six et al., 2008). Loss of AM signaling 
results in severely hypoplastic jugular lymph sacs, whereas 
peripheral lymphatic vessel development is not affected (Fritz-
Six et al., 2008). Systemic administration of AM stimulates 
both lymphangiogenesis and angiogenesis at a site of injury 
to mouse lymphatic vessels (Jin et al., 2008). However, another 
study of RAMP2 gene-targeted mice concludes that the embry-
onic edema observed in these mice is due to hyperpermeable 
blood vessels (Ichikawa-Shindo et al., 2008).
Apoptosis stimulating protein of p53 (Aspp1) is expressed 
specifically in endothelial cells during development. Aspp1 gene-
targeted mice have a disorganized and poorly functional cuta-
neous lymphatic vasculature during embryonic development, 
but some of the functional capacity of the lymphatic vessels is 
restored in adult mice (Hirashima et al., 2008). However, p53 null 
mice have normal lymphatic vessels, indicating that Aspp1 acts 
via other mechanisms in LECs (Hirashima et al., 2008). A sum-
mary of the molecular pathways contributing to development of 
the lymphatic vessels is presented in Table S1.
Development of the Lymph Nodes
The first lymph nodes begin to develop as protrusions of 
connective tissue into the lymph sacs at around E12.5. 
Lymph node induction is initiated by lymphoid tissue 
inducer (LTi) cells of hematopoietic origin, which express 
interleukin-7-receptor-α (IL-7Rα), CD45, and CD4 but lack 
CD3 (Drayton et al., 2006; Mebius, 2003). These cells differ-
Cell 140, February 19, 2010 ©2010 Elsevier Inc. 467
entiate from CD45−/CD4−/CD3− precursor cells in response 
to tumor necrosis factor(TNF)-related activation-induced 
cytokine (TRANCE) (Drayton et al., 2006; Vondenhoff et 
al., 2009a). Notably, signaling via IL-7Rα induces the LTi 
cells to produce lymphotoxin-α1β2 (LTα1β2), a member of 
the TNF family, and to associate with 
mesenchymal organizer cells express-
ing vascular cell adhesion molecule-1 
(VCAM-1), the LTβ-receptor (LTβR), 
TRANCE, and IL-7 (Drayton et al., 2006; 
Mebius, 2003). Both LTα1β2 and LTβR 
are absolutely required for lymph node 
development, which highlights the 
importance of this signaling pathway 
in lymphoid organogenesis (Cupedo 
and Mebius, 2005).
Interestingly, LTα1β2 also induces 
VEGF-C in the organizer cells, sug-
gesting a possible mechanism for the 
induction of developmental lymph node 
lymphangiogenesis (Vondenhoff et al., 2009a). Furthermore, 
at least in superficial analysis, the lymphatic vessels in mice 
lacking LTßR are not affected, indicating that the extranodal 
lymphatic vessel development is not driven via the LTßR 
pathway (Vondenhoff et al., 2009a). Importantly, the lack of 
Figure 4. Lymphatic Vessels in Physio­
logical and Pathological Conditions
(A) Lymphatic vessels (LVs, green) and blood ves-
sels (red) in the tracheal mucosa of a mouse. The 
indentation lacking lymphatic vessels overlies the 
tracheal cartilage ring. 
(B) Sagittal cross-section of a Vegfr3/LacZ mouse 
cranium showing VEGFR-3-positive lymphatic 
vessels (arrowheads) located anteroventrally from 
the cribriform lamina and the olfactory bulb (dot-
ted line). These lymphatic vessels have connec-
tions with the cerebrospinal fluid system (John-
ston et al., 2004). 
(C) Live near-infrared fluorescence lymphangiog-
raphy of the arm (dotted lines) in a healthy human 
subject. The red arrow indicates direction of lymph 
flow toward the axilla. 
Lymphatic vessels (green) and blood vessels (red) 
in the mouse small intestine (D) and the ear skin 
(E). 
(F) Hyperplasia of lymphatic vessels (green) and 
blood vessels (red) in the mouse tracheal mucosa 
following infection with Mycoplasma pulmonis 
(modified from Baluk et al., 2005). 
(G) A mouse lymph node infiltrated by metastatic 
cells (red) originating from a human tumor xeno-
graft. Note the location of the tumor cells near 
LYVE-1 (lymphatic vessel hyaluronan receptor-1) 
positive lymphatic vessels (green). 
(H) Live near-infrared lymphangiography of the 
arm in a patient suffering from lymphedema. Note 
lymph stagnation and leakage. The red arrow indi-
cates direction of the axilla. 
(I) Lymphatic capillary (green) sprouting (arrow-
heads) and release of the CCL27 chemokine (red) 
near green fluorescent protein-positive LNM35 tu-
mor cells (blue) in the mouse ear. 
(J) Abnormal coverage of a lymphatic capillary 
(green) with smooth muscle cells (red) in a FOXC2 
gene-targeted mouse, a model of human lym-
phedema-distichiasis. 
Image (A) courtesy of C. Norrmén. Panels (C) and 
(H) were kindly provided by E. Sevick-Muraca 
(Rasmussen et al., 2009; Sevick-Muraca et al., 
2008). Panel (G) was kindly provided by Y.J. Koh 
and G.Y. Koh.
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lymph sacs does not prevent the early steps of lymph node 
development at least in mice lacking Prox1 (Vondenhoff et 
al., 2009b).
The lymphoid chemokine CXCL13 made by the LTi cells 
activates its receptor CXCR5 in an autocrine loop, leading 
to expression of α4β1 integrin (Drayton et al., 2006; Mebius, 
2003). Stromal cell VCAM-1 activates the integrin, resulting 
in increased expression of adhesion molecules and secreted 
chemokines, such as CCL19, CCL21, CXCL12, and CXCL13 
(Drayton et al., 2006; Mebius, 2003). This leads to the ampli-
fication of both the LTi and the stromal cell populations, and 
presumably also to the differentiation of resident blood vessels 
into high-endothelial venules (Drayton et al., 2006; Mebius, 
2003). The emergence of these vessels allows T and B cells, 
attracted by the same chemokine signals, to enter the lymph 
node from the bloodstream (Cupedo and Mebius, 2005). The 
chemokines are also required for the organization of lymph 
nodes into B cell follicles that are surrounded by T cell zones 
(Cupedo and Mebius, 2005; Drayton et al., 2006).
Continuous influx of antigen-presenting cells through the 
afferent lymphatic vessels is required for the maintenance of 
organized lymph nodes (Mebius et al., 1991). The lymph nodes 
are highly plastic organs, but complete lymph nodes do not 
form after embryogenesis. However, so-called tertiary lym-
phoid organs consisting of clonally expanding B cell follicles 
and T cells are commonly found at sites of chronic inflamma-
tion. The organization of these structures seems to involve 
many of the chemokines involved in lymph node develop-
ment (Drayton et al., 2006; Mebius, 2003). The involvement of 
lymphangiogenic factors and the mechanisms of recruitment 
of lymphatic vessels to such structures are beginning to be 
understood (Furtado et al., 2007).
Lymphatic Vessels and Disease
The lymphatic vessels contribute to a wide range of human pathol-
ogies. A summary of their functions in physiological homeostasis 
and pathological conditions is illustrated in Figure 4.
Inflammation
The lymphatic vessels serve as the principal conduit for soluble 
antigens and antigen-presenting cells from peripheral tissues to 
the lymph nodes and other secondary lymphoid organs. They 
also help to clear other types of leukocytes from sites of resolv-
ing inflammation. The LECs in afferent lymphatic vessels attract 
activated dendritic, T, and B cells expressing the chemokine 
receptor CCR7 by producing its ligand CCL21 (also known as 
secondary lymphoid chemokine, SLC) (Forster et al., 2008). 
Conversely, the CCR10-positive T cells are guided into the affer-
ent vessels by a subpopulation of LECs expressing low levels 
of podoplanin and CCL21 but high levels of the CCR10 ligand 
CCL27 and Duffy blood group antigen receptor for chemokines 
(DARC) (Wick et al., 2008). Leukocyte trafficking in the lymphatic 
vessels appears to also be regulated by cell adhesion molecules 
such as CLEVER-1 (common lymphatic endothelial and vascu-
lar receptor-1) and Mannose receptor 1 (Salmi and Jalkanen, 
2005). An interesting mechanism was recently revealed whereby 
inflamed lymphatic endothelium is able to attenuate dendritic 
cell maturation via CD11b interaction with the ICAM-1 receptor 
in LECs (Podgrabinska et al., 2009).
Sphingosine-1-phosphate (S1P) is a bioactive lipid, syn-
thesized by sphingosine kinases, that is involved in paracrine 
signaling of BECs with pericytes and inflammatory cells. Lym-
phocytes express the G protein-coupled S1P receptor S1P1 
(also known as EDG-1) and exit from the lymph nodes to the 
lymph following a gradient of S1P, likely produced by LECs 
(Ledgerwood et al., 2008; Schwab and Cyster, 2007). S1P1 is 
expressed in LECs, and S1P stimulates lymphangiogenesis in 
vitro as well as in a mouse model (Yoon et al., 2008; Pham et 
al., 2009). Interestingly, LEC-specific deletion of sphingosine 
kinase 1 in a sphingosine kinase 2 gene-targeted background 
inhibits the formation of the button-like junctions in lymphatic 
capillaries in mice (Pham et al., 2009), suggesting that S1P 
regulates lymphatic vessel maturation either directly or by lym-
phocyte-mediated mechanisms.
Antigen-presenting cells such as dendritic cells first reach 
the subcapsular sinus and then move into the paracortex 
where they aggregate around high-endothelial venules (Alva-
rez et al., 2008). This localization allows newly arrived dendritic 
cells to present recently acquired peripheral antigens to both 
B and T cells that constantly enter the lymph node across the 
high-endothelial venules from the blood (Mempel et al., 2004; 
Qi et al., 2006). However, antigens do not necessarily require 
antigen-presenting cells to reach the lymph nodes. Elegant 
studies employing intravital microscopy have elucidated that 
small soluble antigens reach the subcapsular sinus of mouse 
popliteal lymph nodes within minutes following subcutaneous 
injection into the footpad (Roozendaal et al., 2008). Interest-
ingly, extracellular matrix conduits that extend from the sub-
capsular sinus into the B cell follicles enable rapid delivery of 
the small antigens to cognate B cells and follicular dendritic 
cells (Roozendaal et al., 2008). Larger soluble antigens can 
also reach the lymph nodes with the lymph, but they are cap-
tured by resident dendritic cells and macrophages in the corti-
cal region to initiate early T cell priming events already within 
the first four hours following antigenic challenge (Alvarez et al., 
2008). However, it appears that the second wave of antigen-
bearing dendritic cells from the skin is required for inducing 
maximal lymphocyte responses (Alvarez et al., 2008).
Mast cells in the inflamed peripheral tissues were recently 
demonstrated to signal to the draining lymph nodes by releas-
ing stable submicrometer heparin-based particles that contain 
TNF-α and other proteins (Kunder et al., 2009). The complexes 
are taken up by the lymphatic vessels and transported to the 
draining lymph nodes, enabling rapid delivery of proinflam-
matory signaling molecules in concentrated and stable form 
(Kunder et al., 2009). It is conceivable that similar cytokine 
packages are also released by other cell types into the lymph.
Lymphangiogenesis typically occurs at sites of tissue inflam-
mation, for example in immunization and in bacterial infection 
(Alitalo et al., 2005; Baluk et al., 2005). Accordingly, VEGF-C 
is induced in response to proinflammatory cytokines such as 
TNF-α in several cell types, presumably via the activation of 
the NF-κB pathway (Alitalo et al., 2005; Baluk et al., 2009). 
Lymphangiogenesis at sites of inflammatory insults is induced 
by macrophages and granulocytes, which produce ample 
amounts of VEGF-C and VEGF-D (Alitalo et al., 2005; Baluk 
et al., 2005). Blocking these factors with the soluble VEGFR-
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3-Ig ligand trap suppresses lymphangiogenesis and reactive 
lymphadenitis and exacerbates pulmonary edema in a mouse 
model of Mycoplasma pulmonis infection (Baluk et al., 2005). 
Interestingly, lymphangiogenesis is greatly attenuated in T or 
B cell-deficient mice in the M. pulmonis model, possibly due 
to reduced VEGF-D and FGF-2 expression in the inflamed air-
ways (Aurora et al., 2005). Blocking integrin α5β1 signaling with 
small-molecule inhibitors also suppresses lymphangiogenesis 
in this model presumably by directly inhibiting LEC proliferation 
and migration (Okazaki et al., 2009).
The lymphatic vascular system and the molecular pathways 
regulating inflammatory responses are intimately associated, 
and LECs at least in some tissues constitutively express NF-κB 
(Saban et al., 2004). Activation of the NF-κB pathway in LECs 
upregulates Prox1 and VEGFR-3, which renders the lymphatic 
vessels more sensitive to VEGF-C and VEGF-D produced by 
leukocytes (Flister et al., 2009). NF-κB is activated for exam-
ple downstream of Toll-like receptor 4 binding to lipopolysac-
charide in the LECs, which induces activation and production 
of leukocyte chemoattractants such as CCL2, CCL5, and 
CX3CL1 to promote leukocyte homing to the lymphatic vessels 
and eventually to the draining lymph node (Kang et al., 2009). 
Lymphangiogenesis in inflammatory settings facilitates the res-
olution of tissue edema and enhances immune responses by 
promoting macrophage and dendritic cell mobilization (Baluk 
et al., 2005; Kataru et al., 2009). Notably, lymphangiogenesis 
is not observed in atherosclerotic lesions in human coronary 
arteries despite prolonged inflammation and upregulation of 
VEGF-C in the atherosclerotic lesions (Nakano et al., 2005). 
This lack of leukocyte exit routes suggests one reason for the 
accumulation of the so-called foam cells in the atherosclerotic 
intima.
Lymphangiogenesis (sinusoidal hyperplasia) is also observed 
in lymph nodes that drain inflamed tissues (Angeli et al., 2006). 
According to Angeli et al., lymphangiogenesis is stimulated by 
VEGF produced by the follicular B cells in the lymph nodes 
(Angeli et al., 2006). Interestingly, T cells appear to antago-
nize B cell-driven lymphangiogenesis in the lymph node via 
interferon-γ signals, suggesting a mechanism for regression of 
inflammation-induced lymphatic vessels during resorption of 
immune responses (R. Kataru and G.-Y. Koh, personal com-
munication). Also, transforming growth factor β (TGF-β) signal-
ing inhibits the proliferation and migration of cultured human 
LECs as well as lymphangiogenesis in inflammatory settings 
and tumors (Clavin et al., 2008; Oka et al., 2008). Conversely, 
lymphangiogenesis induced by VEGF-C is potentiated in the 
presence of a TGF-β receptor inhibitor in vivo (Oka et al., 2008). 
These findings are in line with the generally anti-inflammatory 
role of TGF-β (Shull et al., 1992).
Lymphangiogenesis is also associated with chronic inflam-
mation, such as psoriasis or rheumatoid arthritis (Alitalo et al., 
2005; Kajiya and Detmar, 2006; Kunstfeld et al., 2004). Elegant 
studies of human kidney transplants show that transplant 
rejection is frequently associated with lymphangiogenesis, and 
that CCL21 produced by host-derived lymphatic vessels in the 
transplant attracts CCR7-expressing dendritic cells (Kerjaschki 
et al., 2004), which elicit primary alloantigen recognition events 
in the lymph nodes that drain the graft. Interestingly, blocking 
VEGFR-3 reduces CCL21 in the allograft LECs and suppresses 
adaptive immune responses toward heart transplants in a 
mouse model (A. Nykänen, H. Sandelin, K. Lemström, K.A., 
et al., unpublished data). These studies indicate that blocking 
lymphangiogenesis and associated dendritic cell migration 
provide an effective anti-inflammatory mode of therapy for the 
prevention of auto- and alloimmunization.
Tumor Metastasis
Regional lymph node metastasis represents the first step of 
tumor dissemination for a variety of common human cancers, 
such as carcinomas of the breast, colon, and prostate as well 
as melanoma (Achen et al., 2005; Karpanen and Alitalo, 2008). 
Currently it is not clear if tumor cells are trapped by lymph 
nodes, resulting in a lag phase in tumor dissemination, if lymph 
node metastases just serve as evidence of tumor cell transit 
through the lymph node, or whether the lymph nodes promote 
spreading of the tumor cells by amplifying the tumor and by 
serving as a launch pad for further systemic metastasis (Joyce 
and Pollard, 2009; Sleeman and Thiele, 2009). The extent of 
lymph node metastasis is a major determinant for the stag-
ing and the prognosis of most human malignancies, which 
often guides therapeutic decisions. Despite this, the molecular 
mechanisms of lymphatic metastasis are incompletely under-
stood.
It is known that tumor cells enter the lymphatic vascula-
ture by invading pre-existing lymphatic vessels in the tumor 
periphery or by eliciting lymphangiogenesis via growth factor 
production (Achen et al., 2005; Alitalo et al., 2005; Tobler and 
Detmar, 2006). The density of lymphatic vessels correlates 
with the incidence of lymph node metastasis and poor prog-
nosis in some human cancers (Achen et al., 2005; Kyzas et 
al., 2005). However, mechanistic studies have elucidated that 
intratumoral lymphatic vessels may be poorly functional due 
to high intratumoral pressure and not required for lymphatic 
metastasis (Padera et al., 2002; Wong et al., 2005). Conversely, 
lymphatic vessels in the tumor periphery are functional and 
can drain colloids from the tumor (Achen et al., 2005; Alitalo 
et al., 2005; He et al., 2005; Padera et al., 2002; Tobler and 
Detmar, 2006). Furthermore, lymphangiogenic growth factors 
produced by tumor cells and tumor-associated macrophages 
stimulate growth and dilation of the peritumoral lymphatic ves-
sels, as well as facilitate tumor cell entry through the lymphatic 
endothelium (Alitalo et al., 2005; Joyce and Pollard, 2009). 
Recent elegant work by Giampieri et al. shows that blocking 
TGF-β signaling prevents breast cancer cells from moving sin-
gly in vivo but does not inhibit collective movement in clus-
ters. Interestingly the cells restricted to collective invasion are 
capable of lymphatic invasion but not blood-borne metastasis 
(Giampieri et al., 2009).
According to a study utilizing anti-colony stimulating fac-
tor-1 (CSF-1) antibodies and small-molecule CSFR-1 receptor 
inhibitors, macrophages are involved in tumor lymphangio-
genesis and metastasis (Kubota et al., 2009). Also other cells 
within the tumor stroma likely contribute to lymphangiogen-
esis induced by tumors. For instance, tumor-associated fibro-
blasts producing high levels of hyaluronan promoted tumor 
lymphangiogenesis, presumably by stimulating malignant 
cells to secrete specific lymphangiogenic factors (Koyama et 
470 Cell 140, February 19, 2010 ©2010 Elsevier Inc.
al., 2008). On the other hand, LECs produce cytokines that 
can guide the tumor cells toward the lymphatic vessels utiliz-
ing similar mechanisms as when attracting leukocytes. For 
example, CCL21 produced by the LECs appears to attract 
some tumor cells that express its receptor CCR7 (Issa et al., 
2009; Shields et al., 2007) (Figure 4I).
VEGF is essential for tumor angiogenesis, and monoclonal 
antibodies targeting this factor have been approved for clini-
cal use in the treatment of several human tumors (Kowanetz 
and Ferrara, 2006). Overexpression of VEGF has also been 
shown to promote tumor lymphangiogenesis and lymph node 
metastasis in experimental models, but it is difficult to assess 
how direct this activity is toward the lymphatic endothelium, as 
VEGF effectively recruits VEGFR-1-expressing macrophages 
that can produce VEGF-C and VEGF-D (Hirakawa et al., 2005). 
Furthermore, blocking VEGFR-2, the key angiogenesis path-
way, inhibits tumor growth and angiogenesis but not lymph 
node metastasis in a prostate tumor model (Burton et al., 2008). 
Nevertheless, a combination of small-interfering RNA (siRNA) 
silencing both VEGF-C and VEGF-A is more effective in sup-
pressing both lymph node and lung metastases in a mouse-
immunocompetent mammary cancer model than knockdown 
of either factor alone (Shibata et al., 2008).
Forced expression of VEGF-C or VEGF-D in xenografts and 
in transgenic tumors results in tumor lymphangiogenesis and 
increased tumor dissemination to regional lymph nodes (Achen 
et al., 2005; Alitalo et al., 2005; Tobler and Detmar, 2006). This 
applies even to tumors that normally do not metastasize to the 
lymph nodes (Achen et al., 2005; Alitalo et al., 2005; Tobler and 
Detmar, 2006). Conversely, inhibiting the VEGFR-3 pathway 
either by the VEGF-C/D Trap or VEGFR-3 blocking antibodies 
suppresses approximately 60%–70% of lymph node metas-
tasis in a variety of experimental tumor models (Achen et al., 
2005; Alitalo et al., 2005; Burton et al., 2008; He et al., 2005; Lin 
et al., 2005; Roberts et al., 2006; Tobler and Detmar, 2006). Also 
NP-2 blocking antibodies have recently been shown to reduce 
tumor lymphangiogenesis and lymph node metastasis at least 
partly by suppressing LEC migration (Caunt et al., 2008).
Studies of human cancers have shown a direct correlation 
between VEGF-C and VEGF-D expression and lymphatic inva-
sion, lymph node and distant organ metastasis, and poor prog-
nosis of survival, but not with the density of tumor-associated 
lymphatic vessels (reviewed in Achen et al., 2005; Alitalo et al., 
2005; Tobler and Detmar, 2006). This observation suggests that 
VEGF-C and VEGF-D qualitatively modulate the lymphatic vas-
culature to promote tumor metastasis. Indeed, studies in mouse 
models utilizing high-resolution imaging demonstrate that the 
lymphangiogenic sprouting stimulated by VEGF-C results in 
the formation of intercellular gaps (Tammela et al., 2007), which 
facilitate tumor cell entry into the lymphatic vessels (Alitalo et 
al., 2005; He et al., 2005). VEGF-C also promotes circumferen-
tial enlargement of the collecting vessels, leading to increased 
lymph flow and transport of tumor cells, as well as accommoda-
tion of larger tumor cell clusters (Alitalo et al., 2005; He et al., 
2005; Hoshida et al., 2006; Ruddell et al., 2008; T.T. et al., unpub-
lished data). Importantly, the collecting lymphatic vessels can 
also act as host tissue for secondary tumor formation at least in 
experimental models (T.T. et al., unpublished data).
Furthermore, lymphangiogenic growth factors produced 
by the primary tumor appear to act at a distance by induc-
ing lymphangiogenesis (sinusoidal hyperplasia) in the sentinel 
lymph node even before the arrival of the first metastatic cells 
(Harrell et al., 2007; Hirakawa et al., 2005, 2007; Kozlowski and 
Hrabowska, 1975). It has been suggested that in this way, the 
tumor cells prepare the “soil” in the lymph node beforehand 
to render it more hospitable for secondary tumor formation 
(Tobler and Detmar, 2006). An elegant study utilizing nonin-
vasive imaging suggests that lymph node lymphangiogenesis 
and increased lymph flow through the tumor-draining lymph 
nodes are B cell dependent, as in inflammatory conditions 
(Harrell et al., 2007).
Lymphatic Insufficiency
Impairment of lymphatic transport capacity due to abnormal 
vessel development or obstruction or obliteration of the lym-
phatic vessels causes stagnation of proteins and associated 
water in the interstitium, resulting in lymphedema, usually a 
progressive and lifelong condition for which curative treatments 
are not available at present. The protein-rich interstitial fluid ini-
tiates a persistent inflammatory response, leading to fibrosis, 
impaired immune responses, and accumulation of subcutane-
ous fat. Lymphedema is classified into primary (congenital) 
lymphedema and secondary (acquired) lymphedema, based 
on the mechanism of pathogenesis (Warren et al., 2007).
Although primary lymphedema is a rare condition, identifi-
cation of the underlying genetic causes has provided valuable 
insight into the molecular mechanisms regulating the develop-
ment and function of the lymphatic vasculature. Heterozygous 
tyrosine kinase-inactivating missense point mutations of the 
VEGFR3 gene have been identified as a major cause of Milroy 
disease (OMIM #153100), a form of lymphedema due to hyp-
oplasia of lymphatic capillaries and typically present at birth 
(Alitalo et al., 2005; Connell et al., 2009; Karpanen and Alitalo, 
2008; Tammela et al., 2007). Mutations in the transcription fac-
tor FOXC2 have been linked to lymphedema-distichiasis (LD, 
OMIM #153400), characterized by late-onset lymphedema, 
a double row of eyelashes, and varicose veins (Maby-El Haj-
jami and Petrova, 2008; Mellor et al., 2007). Analysis of Foxc2 
mutant mice reveals that LD is due to ectopic smooth muscle 
cell and basement membrane coverage of the lymphatic capil-
laries and loss of valves in the collecting vessels (Figure 4J); 
similar defects are also observed in samples obtained from LD 
patients (Petrova et al., 2004). Heterozygous missense muta-
tions in ITGA9 encoding for α9 integrin underlie congenital 
chylothorax in human fetuses (Ma et al., 2008), recapitulating 
the results obtained by gene targeting in mice (Bazigou et al., 
2009; Huang et al., 2000).
Dominant-negative mutations of the homeobox transcrip-
tion factor SOX18 have been linked with hypotrichosis-lym-
phedema-telangiectasia syndrome (HLTS, OMIM #607823) (Irr-
thum et al., 2003). A similar phenotype involving reduced hair, 
blood vessel ruptures, and lymphatic vessel malformations 
is observed in so-called Ragged spontaneous mutant mice, 
which harbor a single-base frameshift mutation in SOX18 that 
abolishes transcriptional transactivation (Francois et al., 2008; 
Pennisi et al., 2000). Finally, mutations in the NF-κB regulatory 
protein NEMO associate with a rare and complex syndrome 
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involving lymphedema (anhidrotic ectodermal dysplasia with 
immunodeficiency, osteopetrosis, and lymphedema, OL-EDA-
ID, OMIM #300301) (Döffinger et al., 2001; Saban et al., 2004). 
Interestingly, mutations in human collagen and calcium-binding 
protein-1 (CCBE1) were recently found to underlie lymphatic 
vessel dysplasia in primary lymphedema patients (Alders et 
al., 2009), suggesting a conserved function for this gene in the 
regulation of lymphatic vessel development from zebrafish to 
mammals (Hogan et al., 2009).
Over 99% of lymphedema cases worldwide are secondary to 
acquired damage to the lymphatic vessels (Radhakrishnan and 
Rockson, 2008; Warren et al., 2007). Filariasis (elephantiasis) is 
an infection of the lymphatics by the parasitic worms Wuchere-
ria bancrofti, Brugia malayi, or Brugia timori, which leads to 
obstruction and scarring of lymphatic vessels and chronic lym-
phedema of the lower limbs or genital organs. The onset of filari-
asis is triggered by a filarial-specific inflammatory reaction that 
stimulates the production of VEGF, VEGF-C, and VEGF-D, which 
leads to persistent hyperplasia of the lymphatic vessels (Pfarr et 
al., 2009). Interestingly, individuals with genetically attenuated 
immune responses to the filaria appear to develop markedly 
milder forms of the disease (Pfarr et al., 2009). Filariasis is the 
principal cause of lymphedema worldwide, affecting approxi-
mately 100 million people (Hoerauf, 2006; Pfarr et al., 2009).
Breast cancer surgery is the leading cause for secondary 
lymphedema in industrialized countries (Alitalo et al., 2005; 
Radhakrishnan and Rockson, 2008). The metastatic tumor 
cells that frequently spread to the lymph nodes necessitate 
radical surgery and radiotherapy, which destroy the lymphatic 
vessel network and lead to impairment of afferent lymphatic 
flow (Alitalo et al., 2005; Radhakrishnan and Rockson, 2008; 
Warren et al., 2007). For example, approximately 20%–30% of 
patients that have undergone radical axillary lymph node dis-
section develop lymphedema of the upper limb later on (Clark 
et al., 2005; Warren et al., 2007). The predisposition to develop 
post-lymphadenectomy lymphedema appears to depend on 
genetic factors, but susceptibility genes have thus far not been 
identified (Radhakrishnan and Rockson, 2008; Warren et al., 
2007). Damage to the lymphatics may also result from bacterial 
infections of the skin (such as erysipelas) or the lymphatic ves-
sels (lymphangitis), which are typically caused by streptococ-
cal or staphylococcal infections, respectively (Radhakrishnan 
and Rockson, 2008; Warren et al., 2007).
Unlike primary lymphedema, secondary lymphedema is typi-
cally due to damage to the collecting lymphatic vessels. Sponta-
neous recanalization of collecting vessels may occur in minimal 
lesions, but formation of new lymphatic vessels is typically not 
observed in lymphedema patients, although pre-existing ves-
sels dilate to accommodate the increased fluid (Ikomi et al., 
2006; Stanton et al., 2009; Tabibiazar et al., 2006). Hypoxia is a 
ubiquitous stimulus for the initiation of angiogenesis, but it is not 
known if, analogously, intrinsic edema-induced mechanisms for 
engaging lymphangiogenic gene expression programs exist.
The treatment of lymphedema is currently based on phys-
iotherapy, compression garments, liposuction, and occasion-
ally surgery (Radhakrishnan and Rockson, 2008; Warren et 
al., 2007), but means to reconstitute the collecting lymphatic 
vessels and cure the condition are rarely successful (Baumeis-
ter et al., 1981; Becker et al., 2006). VEGF-C gene transfer via 
adenoviruses, adeno-associated viruses, or naked plasmids, 
as well as the application of recombinant VEGF-C protein stim-
ulate the formation of new lymphatic capillaries and alleviate 
edema in preclinical animal models of lymphedema (Alitalo et 
al., 2005), pointing to possibilities to restore lymphatic vessels 
in lymphedema patients.
As a therapeutic advance, we recently showed that lym-
phatic capillaries induced by adenoviral VEGF-C or VEGF-D 
expression mature into collecting vessels in a mouse model of 
axillary lymph node dissection (Tammela et al., 2007). Recom-
binant VEGF-C has also been shown to promote collecting 
vessel formation after removal of popliteal lymph nodes (Ikomi 
et al., 2008). There are few known molecular players that regu-
late lymphatic vessel maturation in adult tissues. Whether the 
lymphatic vessels mature or not appears to be tissue specific, 
as lymphatic capillaries induced by VEGF-C do not acquire all 
hallmarks of collecting vessels in mouse ear (T.T. et al., unpub-
lished data). Therefore it is likely that lymph flow in the nascent 
vessels contributes to the remodeling (Ng et al., 2004). Nota-
bly, VEGF-C is also a chemoattractant for monocytes/mac-
rophages, and these cells may also play a role in lymphatic 
vessel maturation (Saaristo et al., 2006; Skobe et al., 2001). 
Prolonged VEGF-C stimulation may also directly promote LEC 
differentiation.
In order to comprehensively restore the anatomy of the axilla 
following surgery, combined VEGF-C therapy with lymph node 
transplantation was applied in mice (Tammela et al., 2007). The 
lymph nodes transduced with adenoviral VEGF-C survive, form 
connections with the pre-existing lymphatic vessel network, 
and can trap metastatic tumor cells, whereas the majority of 
control-treated nodes regress, indicating that VEGF-C therapy 
can improve the success rate of lymph node transplantation 
(Becker et al., 2006; Tammela et al., 2007). Importantly, the 
combination of VEGF-C gene transfer and lymph node trans-
plantation also appears successful in a porcine model, indicat-
ing the feasibility of such an approach for humans (M. Lähteen-
vuo, T. Tervala, A. Saaristo, K.A., et al., unpublished data).
Interestingly, artificial lymph nodes composed of collagen 
scaffolds have been shown to attract lymphocytes, which 
elicit immune responses in mouse models, suggesting an 
approach for the replacement of damaged lymph nodes or for 
the augmentation of regional immune responses (Okamoto et 
al., 2007). This approach and VEGF-C/D therapy should be an 
attractive combination for the future.
Obesity and Fat Metabolism
The lymphatic vessels are essential for the adsorption of hydro-
phobic nutrients, such as triglycerides, cholesterol, and other 
lipid molecules from the small intestine. The enterocytes lining the 
intestinal villi package these molecules into water-soluble chylo-
microns 75 to 1200 nm in diameter and secrete them to the ablu-
menal side. The chylomicrons are taken up by a centrally located 
lymphatic vessel in the villus, called the lacteal due to the milky 
appearance of the lipid-rich intestinal lymph. The lacteal vessels 
connect with larger mesenterial collecting vessels. In fact, the 
first mention of lymphatic vessels in the literature dates from 1627 
when the Italian anatomist Gasparo Aselli observed “milky veins” 
(lacteis venis) in the mesentery of a dog that had just been fed.
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Prox1 is required for the maintenance of LECs. Prox1 heterozy-
gous mice that survive until adulthood, as well as mice with an 
endothelial-specific deletion of Prox1, develop late-onset chy-
lous ascites and obesity, indicating a link between impaired 
lymph drainage and tissue adiposity (Harvey et al., 2005). Inter-
estingly, human and mouse lymphedema are also characterized 
by the accumulation of fat in peripheral tissues such as the sub-
cutaneous space (Alitalo et al., 2005; Radhakrishnan and Rock-
son, 2008; Warren et al., 2007). These observations suggest 
that the cutaneous lymphatic vessels may be required for lipid 
metabolism or mobilization of tissue fat reserves much like in the 
small intestine. Alternatively, lymph may contain adipogenic fac-
tors, which need to be cleared by the lymphatic vessels in order 
to maintain tissue architecture (Harvey, 2008).
Hypertension
As mentioned above, the lymphatic vessels are specialized for 
the uptake of fluid and macromolecules from the interstitium, 
which is essential for the maintenance of tissue fluid homeo-
stasis. Recent exciting work by Machnik et al. suggests that 
the lymphatic vessels proliferate in response to a high-salt diet, 
possibly via upregulation of VEGF-C in monocytic cells infiltrat-
ing the interstitium of the skin (Machnik et al., 2009). Blocking 
lymphangiogenesis with VEGFR-3-Ig appears to increase the 
blood pressure of the salt-loaded, but not control mice, sug-
gesting that the lymphatic vessel hyperplasia is required in the 
regulation of salt storage to the interstitium. On the other hand, 
VEGF-C can also lower the blood pressure directly via a VEG-
FR-2/eNOS-mediated mechanism (Machnik et al., 2009; T.T. 
and G. Zarkada, unpublished data). At least tonicity-responsive 
enhancer binding protein (TonEBP) and lens epithelium-derived 
growth factor (LEDGF/p75) stimulate VEGF-C transcription in 
conditions of cellular stress (Cohen et al., 2009; Machnik et al., 
2009). Further work should clarify if these observations can lead 
to additional modalities of blood pressure control.
Conclusions
Because of the specific functions of the lymphatic vessels in the 
maintenance of tissue fluid balance, immunosurveillance, and the 
uptake of dietary fats, they differ greatly from the blood vessels in 
their structure, their function, and the molecular mechanisms that 
regulate their development and growth. Considerable progress 
has been made in the elucidation of these mechanisms during the 
past years, mainly because of the use of molecular genetic analy-
ses in mouse, zebrafish, and Xenopus as well as comparison of 
LECs and BECs in cell biological and transcriptional studies. The 
lymphatic vascular system actively facilitates tumor metastasis, as 
well as the elicitation of auto- and alloimmune responses. Inhibit-
ing lymphangiogenesis in such settings appears to be a promis-
ing therapeutic avenue. Conversely, stimulation of lymphatic ves-
sel growth with factors such as VEGF-C or VEGF-D has become 
a realistic treatment modality for patients suffering from lymphatic 
insufficiency or tissue edema. Such progress should provide cli-
nicians with therapeutic targeting of the lymphatic system in the 
treatment of an expanding spectrum of human pathologies.
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